In the Diuretic Optimization Strategies Evaluation (DOSE), the vexing issue of optimal administration of furosemide in patients with acute decompensated heart failure was tackled. In addition to the trial providing results that are clinically relevant, it also provides a model for future drug trials by addressing parameters such as dose, method of delivery, and duration of therapy.
Hallmarks of congestive heart failure (CHF) are sodium and water retention, and the resulting symptoms are related to conges tion. Worsening CHF often results in acute decom pensated heart failure (ADHF), requir ing hospitalization. The mainstay of therapy for CHF is the use of intravenous diuret ics to improve symptoms and to stabilize this precarious clinical syndrome. Although diuretic therapy in some form is centuries old, conflicting results from preclinical and clinical investigations fuel the ongoing contro versy regarding the safety and effi cacy of diuretics such as furosemide in the clinical setting of ADHF. Thus, prospective assessment of the safety and efficacy of furo semide in both ADHF and chronic CHF is long overdue, and is a high priority in clinical cardiovascular medicine.
Felker and colleagues have addressed this highly relevant question in the first clinical trial reported by the National Heart, Lung and Blood Institute (NHLBI) Clinical Heart Failure Research Network, which was est ablished in June 2006. 1 In the multicenter, randomized controlled Diuretic Optimiz ation Strategies Evaluation (DOSE), 1 of 308 patients hospitalized for ADHF, four diuretic strate gies utilizing furosemide were assessed. Following hospitalization, patients were ran domly assigned to receive continuous intra venous infusion of furosemide, or an acute intra venous bolus of this drug every 12 h, for 72 h. In addition, each group received a dose of furosemide that was either equal to (low dose) or 2.5times higher than (high dose) the oral dose of furosemide that they were receiving before hospitalization. The study design was founded upon important clinical issues from previous investi gations, which support the hypothesis that intravenous continuous administration of furosemide might be more effective in improving symp toms and could be associated with reduced impairment of renal function. 2, 3 Thus, this seminal trial addressed clinically relevant questions that could have a major impact on clinical practice in the broad area of CHF, the most common diagnosis among hospitalized elderly individuals.
The findings of this trial were not predict able. Importantly, no differences between furosemide bolus and infusion were reported with respect to dyspnea, a novel global clinical assessment score, or renal function (specifi cally serum creatinine level). 1 A trend toward clinical improvement with highdose versus lowdose furosemide was shown. However, the benefits associated with the high dose were tempered by worse renal function or a higher serum creatinine level than with the low dose. Importantly, although the study was not powered to address longterm outcomes, no significant differences in the composite end point of death, rehospitalization, or emer gency department visit at 60 days was evident for either furosemide bolus versus infusion, or for highdose versus lowdose furosemide. Nevertheless, the fact that a high rate of this composite end point occurred across all treatment groups in this serious clinical con dition is disappointing, but unfortunately not surprising. 1 The investigators and the NHLBI Clinical Heart Failure Research Network are to be congratulated on completing a very difficult clinical study, which advances our under standing of the use of furosemide in patients with ADHF. One must conclude that, in the acute setting, there appears to be no superior ity of infusion or bolus furosemide therapy. This information was collected by the investi gators in a rigorous manner and is important to the clinician. To speculate that acute, high dose furosemide might have greater clinical benefit than lowdose therapy with regard to symptoms is tempting, although this benefit is moderated by a transient worsening of renal function. Nonetheless, lack of worse outcomes in the setting of transient renal dysfunction should be reassuring and may be consistent with the observation of Shannon et al. that transient changes in renal function, especi ally worsen ing renal function, during vigo rous treatment of congestion in patients with ADHF might not necessarily translate into adverse cardio vascular outcomes, such as increased mortality and morbidity. 4 Some cautionary points about DOSE 1 should be made. One cannot ignore existing data from preclinical animal models of heart failure, which suggest that furosemide might worsen myocyte function via neuro humoral mechanisms and contribute to increased mortality. 5 Furthermore, large clinical trials such as the Studies Of Left Ventricular Dysfunction (SOLVD) 6 have established 
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that highdose potassium wasting diure tics are associated with increased mortal ity. In addition, indepth studies have clearly demon strated adverse actions of furosemide on renal function in addition to activation of the renin-angiotensinaldosterone system. 7, 8 Therefore, although we are confident in acting upon the find ings of this important clinical trial by Felker and colleagues, further studies are required to address the longterm impact of diuretic therapy on cardiorenal structure and func tion and, most importantly, on clinical outcomes. DOSE 1 should mark the begin ning of aggressive investi gative strategies to further understand the role of diuretics in human CHF.
In the elegant editorial 9 accompanying the results of DOSE 1 in the New England Journal of Medicine, Fonarow noted that the unacceptably high mortality associated with ADHF was also observed in DOSE. Therefore, we underscore his call for the development of innovative drugs targeting ADHF and for the development of strategies for the prevention of heart failure; perhaps through biomarker analyses, which could identify highrisk patients before the onset of symptomatic CHF. 10 New therapeutics for ADHF should not only focus on symp toms related to congestion, but also cellular targets such as the cardiomyocyte, the fibro blast, the endo thelium, or key cell types in the kidney and other organs that dysfunc tion in patients with heart failure. Also, as 'blue printed' in DOSE, 1 for any new thera peutic we must consider appropriate doses, delivery methods, and duration of delivery early in the development process. By rigo rously addressing these points, we can best evaluate the extent to which a new drug can reduce the ever increasing burden of cardiovascular disease. 
